Toll-like receptor 4 in COVID-19: friend or foe?

被引：37
|
作者：
Mukherjee, Suprabhat [1 ]
机构：
[1] Kazi Nazrul Univ, Dept Anim Sci, Integrat Biochem & Immunol Lab, Asansol 713340, W Bengal, India
来源：
FUTURE VIROLOGY | 2022年 / 17卷 / 07期
关键词：
COVID-19; cytokine storm; immunotherapy; SARS-CoV-2; TLR4; TLR4;
D O I：
10.2217/fvl-2021-0249
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Tweetable abstract Toll-like receptor 4, an innate immune sensor, is one of the key 'fate-deciding' regulators of immunity as well as COVID-19 immunopathogenesis. Suitable targeting of Toll-like receptor 4 appears to be an effective strategy to counteract the pandemic.
引用
收藏
页码：415 / 417
页数：3
相关论文
共 50 条
  • [1] Toll-like receptor signalling in regenerative myogenesis: friend and foe
    Hindi, Sajedah M.
    Kumar, Ashok
    JOURNAL OF PATHOLOGY, 2016, 239 (02): : 125 - 128
  • [2] Toll-like receptor 3 in viral pathogenesis: friend or foe?
    Perales-Linares, Renzo
    Navas-Martin, Sonia
    IMMUNOLOGY, 2013, 140 (02) : 153 - 167
  • [3] Toll-like receptor 9 in murine lupus: More friend than foe!
    Yu, Philipp
    Musette, Philippe
    Peng, Stanford L.
    IMMUNOBIOLOGY, 2008, 213 (02) : 151 - 157
  • [4] Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments
    Liu, Zhi-Mei
    Yang, Ming-Hui
    Yu, Kun
    Lian, Zheng-Xing
    Deng, Shou-Long
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Serum soluble toll-like receptor 4 and risk for clinical severity in COVID-19 patients
    Maha E. Houssen
    Marwa O. Elmaria
    Dina Badr
    Rasha El-Mahdy
    Mayada A. Ghannam
    Shaimaa El-Ashwah
    May Denewer
    Metwaly Ibrahim Mortada
    Pneumonia, 16
  • [6] Serum soluble toll-like receptor 4 and risk for clinical severity in COVID-19 patients
    Houssen, Maha E.
    Elmaria, Marwa O.
    Badr, Dina
    El-Mahdy, Rasha
    Ghannam, Mayada A.
    El-Ashwah, Shaimaa
    Denewer, May
    Mortada, Metwaly Ibrahim
    PNEUMONIA, 2024, 16 (01)
  • [7] Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities?
    Brandao, Simone Cristina Soares
    Ramos, Julia de Oliveira Xavier
    Dompieri, Luca Terracini
    Godoi, Emmanuelle Tenorio Albuquerque Madruga
    Figueiredo, Jose Luiz
    Sarinho, Emanuel Savio Cavalcanti
    Chelvanambi, Sarvesh
    Aikawa, Masanori
    CYTOKINE & GROWTH FACTOR REVIEWS, 2021, 58 : 102 - 110
  • [8] NSAIDs in COVID-19, friend or foe?
    Abaalkhayl, Mohammed Soliman
    ANAESTHESIA PAIN & INTENSIVE CARE, 2022, 26 (04) : 554 - 558
  • [9] Testosterone in COVID-19: Friend or Foe?
    Peter J. Niemann
    Heidi V. Goldstein
    Endocrine, 2021, 71 : 281 - 282
  • [10] Estrogen and COVID-19: friend or foe?
    Di Vincenzo, A.
    Andrisani, A.
    Vettor, R.
    Rossato, M.
    ANNALS OF ONCOLOGY, 2021, 32 (07) : 934 - 934
12345